Europe approves Janssen-Cilag's Invega for schizoaffective disorder
This article was originally published in Scrip
Executive Summary
Janssen-Cilag, International , the Johnson & Johnson company, has won approval from the European Commission for Invega (paliperidone ER) to be used to treat psychotic or manic symptoms of schizoaffective disorder. The decision follows the positive recommendation, made last September, by the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency's (EMA) scientific committee.